Oncology
4 drugs are in development for Renal Cell Carcinoma.
- Companies
- 4
- Clinical trials
- 55
Prepared research question
Which programs lead the Renal Cell Carcinoma pipeline—and what evidence could change the picture?
Traceable citations · Unknowns marked
Drug Pipeline by Phase
| Drug | Company |
|---|---|
| Lorigerlimab | MACROGENICS INC (MGNX) |
| Drug | Company |
|---|---|
| itil-306 | Instil Bio, Inc. (TIL) |
| JANX008 | Janux Therapeutics, Inc. (JANX) |
About this indication
Renal Cell Carcinoma context
Also known as: Adenocarcinoma Of Kidneys, Adenocarcinomas, Renal Cell, Cancer, Renal Cell, Carcinoma, Nephroid, Carcinoma, Renal, Carcinomas, Renal Cell, Kidney, Adenocarcinoma Of, Nephroid Carcinomas, Renal Adenocarcinoma, Renal Adenocarcinomas, Renal Carcinomas, Renal Cell Adenocarcinoma, Renal Cell Cancers
Narrower concepts tracked separately: Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma (ccRCC)
Prevalence
48.0 / 100K
Incidence
15.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Renal Cell Carcinoma?
BioSniper tracks 4 drugs in development for Renal Cell Carcinoma across 4 companies.
How many clinical trials target Renal Cell Carcinoma?
There are 55 clinical trials targeting Renal Cell Carcinoma tracked by BioSniper.
What is the prevalence of Renal Cell Carcinoma?
The estimated prevalence of Renal Cell Carcinoma is approximately 48.0 per 100,000 population.